Vistagen Therapeutics Inc Stock Price, News & Analysis

VistaGen Therapeutics (Nasdaq: VTGN) reports progress in its late-stage clinical programs for PH94B, targeting social anxiety disorder (SAD), with topline data from PALISADE-1 and PALISADE-2 trials expected in mid-2022 and the second half of 2022, respectively. The company has initiated the PALISADE Long-term Safety Study and a Phase 2A trial for adjustment disorder with anxiety (AjDA). Additionally, a Phase 2B study for PH10 in major depressive disorder (MDD) is set to commence in late 2022. The net loss for Q3 2022 was approximately $10.5 million, with cash reserves of $83.7 million as of December 31, 2021.

VistaGen Therapeutics (NASDAQ: VTGN) announced a conference call scheduled for February 10, 2022, at 2:00 PM PT to discuss its financial results for the third quarter of fiscal year 2022, which ended December 31, 2021. The call aims to review recent accomplishments and outline upcoming milestones for the company, focusing on its commitment to developing innovative medicines for CNS disorders. A live audio webcast will be accessible, and a recorded playback will be available afterward.

VistaGen Therapeutics (NASDAQ: VTGN) has announced that Chief Executive Officer, Shawn Singh, will participate in a fireside chat with Jefferies analyst Andrew Tsai at the Jefferies Virtual London Healthcare Conference on November 18, 2021. The company focuses on developing innovative medicines for anxiety, depression, and other central nervous system disorders. A webcast of the presentation will be available on VistaGen's website for 30 days post-conference, emphasizing their commitment to advancing treatments beyond current standards of care.

VistaGen Therapeutics (NASDAQ: VTGN) announced progress in its ongoing PALISADE Phase 3 clinical trials for PH94B, aimed at treating social anxiety disorder (SAD). The company initiated a second Phase 3 trial, PALISADE-2, and reported increased R&D expenses of $10.1 million due to advancements in clinical programs. While the revenue rose slightly to $0.4 million, the net loss for the quarter reached $12.8 million. VistaGen remains committed to expanding PH94B's potential beyond SAD, with a focus on adjustment disorder with anxiety (AjDA) and other anxiety indications.

VistaGen Therapeutics (NASDAQ: VTGN) announced a conference call and webcast to discuss its Q2 financial results for FY 2022. This event will take place on November 10, 2021, at 5:00 p.m. ET. The call will review the company's financial performance for the quarter ending September 30, 2021, alongside recent achievements and future milestones. Interested parties can join via U.S. or international dial-in or through a live audio webcast. VistaGen focuses on developing innovative treatments for anxiety, depression, and other CNS disorders.

VistaGen Therapeutics (NASDAQ: VTGN) has initiated a Phase 2A clinical trial for PH94B, targeting Adjustment Disorder with Anxiety (AjDA), while concurrently advancing its Phase 3 studies for Social Anxiety Disorder (SAD). This randomized, double-blind study will enroll around 40 adults in Boston and New York, measuring anxiety changes using the Hamilton Anxiety Rating Scale. PH94B is an investigational nasal spray that aims for rapid anti-anxiety effects without systemic uptake or benzodiazepine-like side effects.

VistaGen Therapeutics (NASDAQ: VTGN) announced promising results from a preclinical study on its investigational drug PH94B, which may offer a new mechanism of action for treating anxiety without the risks associated with benzodiazepines. The study revealed that PH94B is primarily confined to the nasal passages with minimal presence in the brain, suggesting limited systemic exposure. This aligns with previous findings that it does not activate GABA-A receptors. The ongoing PALISADE Phase 3 Program aims to establish PH94B as a fast-acting treatment option for over 23 million Americans suffering from Social Anxiety Disorder.

VistaGen Therapeutics (NASDAQ: VTGN) has initiated PALISADE-2, a Phase 3 clinical trial evaluating PH94B as a rapid treatment for adults with social anxiety disorder (SAD). This randomized, multi-center, double-blind study aims to replicate findings from PALISADE-1 and a prior Phase 2 trial, which showed significant anxiety reduction within 15 minutes (p=0.002). Approximately 208 patients will participate across 15 sites in the U.S. Successful outcomes may lead to a New Drug Application to the FDA in 2023.

VistaGen Therapeutics (NASDAQ: VTGN) announced participation in Baird’s 2021 Global Healthcare Conference on September 14, 2021, at 12:10 p.m. PT. CEO Shawn Singh will lead a fireside chat and engage in one-on-one meetings during the two-day event. A live webcast of the presentation will be available on the Investors section of VistaGen's website. The company focuses on developing innovative medicines for anxiety, depression, and other CNS disorders, with three drug candidates currently showing promise in clinical studies.